HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Second Time Lucky? Sumatriptan One Of Three Switches On The Cards In Germany

Executive Summary

A second attempt at switching sumatriptan for migraines, as well as switch applications for non-steroidal anti-inflammatories ketoprofen and liquid ibuprofen, are all on the agenda at Germany's next Expert Committee for Prescription meeting in June. 

You may also be interested in...



Stada Says Lemocin’s OTC Status 'Vindicated' By German Switch Committee Decision

Stada's Lemocin cough lozenges survive a German reverse-switch threat, as does first generation anti-histamine dimenhydrinate, pointing to possible good news for the company's other major German OTC brand, Hoggar Night (doxylamine), which is also having its OTC status re-examined by the country's Expert Committee on Prescription.

Stada Blasts German Sleep Aid Reverse Switch

Stada criticizes German switch committee's recommendation to restrict access to first generation antihistamines with a sedative effect for over-65s. 

German Switch Committee Meets: Sumatriptan Goes Again, Antihistamine Reverse-Switch Rejected, For Now

Germany’s Expert Committee for Prescription recommends prescription-to-OTC reclassifications of sumatriptan for migraines and liquid ibuprofen, but rejects an OTC switch for ketoprofen and the reverse-switch of sedative antihistamines for over 65s.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel